Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Percheron Therapeutics.
RELATED STOCKHEAD STORIES
News
Trading Places: Here are this week’s substantial holder movements
Health & Biotech
Health: FDA approval is eye candy for Visioneering’s kiddie contact lens
Health & Biotech
These are the 22 small cap biotechs closest to bringing a drug to market
Health & Biotech
The life sciences investment wave is building. Here’s how to ride it.
News
Lunchtime ASX small cap wrap: Who’s blaming the umpiring today?
Stockhead TV
Video: 90 Seconds With… Mark Diamond, Antisense Therapeutics
Health & Biotech
Check-up: Medicinal cannabis investment puts an energy company in top spot
News
Lunchtime ASX small cap wrap: Who’s pointing the finger today?
Health & Biotech
Health: Cynata has finally scored that Fujifilm deal; shares climb 27pc
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Dr Boreham’s Crucible: Antisense wants to conquer the less crowded DMD market
News
Lunchtime ASX small cap wrap: Who’s planning for the future?
Health & Biotech
Biotech entrepreneur Paul Hopper tells us why he joined ‘treasure chest’ Suda
Health & Biotech
Antisense Therapeutics looks to give boys a lifeline; launches DMD Phase 2 trial
Health & Biotech
Could Antisense be the next multi-billion Duchenne Muscular Dystrophy biotech?
Health & Biotech
Antisense is about to start its muscular dystrophy trial
Health & Biotech
